Co-Diagnostics, Inc. Common Stock (CODX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $2.72M
Last updated: Nov 17, 2026 at 11:03 AM ET
Co-Diagnostics, Inc. Common Stock (CODX) Earnings: Report Dates and Results
Co-Diagnostics, Inc. Common Stock (CODX) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Co-Diagnostics, Inc. Common Stock reported EPS of -$1.02, above the -$1.25 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CODX has an expected report date of Mar 29, 2027.
CODX Earnings Call
The latest CODX earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 32 quarters below that had an estimate, CODX beat 14, missed 17 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $282881, up 94.6% from $145380 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.02 | -$1.25 | -$1.25 - -$1.25 | +18.80% | Beat | N/A | 1 | 1 up, 0 down | Nov 10, 2026 | $282881 |
| Jun 30, 2026 | -$1.46 | -$3.00 | -$3.00 - -$3.00 | +51.33% | Beat | N/A | 1 | 0 up, 1 down | Aug 13, 2026 | $166131 |
| Mar 31, 2026 | -$4.09 | -$3.75 | -$3.90 - -$3.60 | -9.07% | Miss | N/A | 2 | 0 up, 1 down | May 14, 2026 | $145954 |
| Dec 31, 2025 | -$4.44 | -$3.90 | -$3.90 - -$3.30 | -13.70% | Miss | N/A | 2 | 1 up, 0 down | Mar 31, 2026 | $263922 |
| Sep 30, 2025 | -$4.66 | -$5.70 | N/A | +18.25% | Beat | N/A | 1 | 0 up, 1 down | Nov 13, 2025 | $145380 |
| Jun 30, 2025 | -$7.01 | -$7.50 | N/A | +6.53% | Beat | N/A | 1 | 1 up, 0 down | Aug 14, 2025 | $162910 |
| Mar 31, 2025 | -$7.72 | -$9.90 | N/A | +22.02% | Beat | N/A | 1 | 1 up, 0 down | May 8, 2025 | $50277 |
| Dec 31, 2024 | -$0.38 | -$0.34 | -$0.34 - -$0.34 | -11.12% | Miss | N/A | 1 | 0 up, 1 down | Mar 27, 2025 | $149325 |
| Sep 30, 2024 | -$9.82 | -$9.90 | N/A | +0.81% | Beat | N/A | 1 | 0 up, 0 down | Nov 7, 2024 | $641141 |
| Jun 30, 2024 | -$7.50 | -$10.20 | N/A | +26.47% | Beat | N/A | 1 | 0 up, 0 down | Aug 8, 2024 | $2.66M |
| Mar 31, 2024 | -$9.81 | -$6.30 | N/A | -55.71% | Miss | N/A | 1 | 0 up, 0 down | May 9, 2024 | $467854 |
| Dec 31, 2023 | -$0.50 | -$0.20 | -$0.20 - -$0.20 | -150.00% | Miss | N/A | 1 | 0 up, 0 down | Mar 14, 2024 | $3.56M |
| Sep 30, 2023 | -$6.54 | -$8.70 | N/A | +24.83% | Beat | N/A | 1 | 0 up, 0 down | Nov 9, 2023 | $2.46M |
| Jun 30, 2023 | -$9.50 | -$7.20 | N/A | -31.94% | Miss | N/A | 1 | 0 up, 0 down | Aug 10, 2023 | $197806 |
| Mar 31, 2023 | -$6.91 | -$7.20 | -$7.21 - -$6.31 | +4.03% | Beat | -190.4% | 2 | 0 up, 0 down | May 11, 2023 | $601957 |
| Dec 31, 2022 | -$0.68 | -$0.15 | -$0.15 - -$0.15 | -353.33% | Miss | -372.0% | 3 | 0 up, 0 down | Mar 16, 2023 | $1.40M |
| Sep 30, 2022 | -$2.38 | -$1.00 | -$2.40 - $0.60 | -138.00% | Miss | -120.9% | 4 | 0 up, 0 down | Nov 10, 2022 | $5.09M |
| Jun 30, 2022 | -$2.91 | $2.10 | $0.00 - $4.50 | -238.57% | Miss | -129.4% | 3 | 0 up, 0 down | Aug 11, 2022 | $5.02M |
| Mar 31, 2022 | $7.64 | $5.10 | N/A | +49.80% | Beat | -2.1% | 3 | 0 up, 0 down | May 12, 2022 | $22.70M |
| Dec 31, 2021 | $0.25 | $0.12 | $0.08 - $0.15 | +108.33% | Beat | -44.4% | 3 | N/A | Mar 24, 2022 | $20.40M |
| Sep 30, 2021 | $11.40 | $6.30 | $6.01 - $6.31 | +80.95% | Beat | -28.3% | 3 | 1 up, 0 down | Nov 11, 2021 | $30.10M |
| Jun 30, 2021 | $9.90 | $6.60 | $6.31 - $6.91 | +50.00% | Beat | -23.3% | 3 | N/A | Aug 12, 2021 | $27.36M |
| Mar 31, 2021 | $7.80 | $6.00 | N/A | +30.00% | Beat | N/A | 2 | N/A | May 13, 2021 | $20.02M |
| Dec 31, 2020 | $0.45 | $0.48 | $0.46 - $0.49 | -6.25% | Miss | N/A | 3 | N/A | Mar 25, 2021 | $27.15M |
| Sep 30, 2020 | $15.90 | $21.15 | $14.71 - $26.13 | -24.82% | Miss | N/A | 3 | N/A | Nov 16, 2020 | $21.82M |
| Jun 30, 2020 | $12.90 | $19.50 | $13.81 - $20.72 | -33.85% | Miss | N/A | 3 | N/A | Aug 13, 2020 | $24.04M |
| Mar 31, 2020 | -$1.50 | -$1.20 | -$2.40 - -$1.20 | -25.00% | Miss | N/A | 3 | N/A | May 14, 2020 | $1.55M |
| Dec 31, 2019 | -$0.09 | -$0.09 | -$0.10 - -$0.08 | 0.00% | In line | N/A | 3 | N/A | Mar 30, 2020 | $108566 |
| Sep 30, 2019 | -$3.00 | -$2.25 | -$2.40 - -$2.10 | -33.33% | Miss | N/A | 2 | N/A | Nov 13, 2019 | $41434 |
| Jun 30, 2019 | -$2.40 | -$1.65 | -$2.40 - -$0.90 | -45.45% | Miss | N/A | 2 | N/A | Aug 14, 2019 | $61574 |
| Mar 31, 2019 | -$2.70 | -$2.40 | -$2.40 - -$2.40 | -12.50% | Miss | N/A | 2 | N/A | Apr 2, 2019 | $3400 |
| Dec 31, 2018 | -$0.15 | -$0.13 | -$0.13 - -$0.13 | -15.38% | Miss | N/A | 1 | N/A | Dec 31, 2018 | $10823 |
| Sep 30, 2018 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2018 | $9696 |
| Jun 30, 2018 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 10, 2018 | $9696 |
| Mar 31, 2018 | -$0.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 14, 2018 | $9696 |
| Dec 31, 2017 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 28, 2018 | $2598 |
| Sep 30, 2017 | -$0.33 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 | $2598 |
| Jun 30, 2017 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 25, 2017 | $2466 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$23.83, after -$27.51 the year before. It was -$0.52 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$23.83 | N/A |
| Dec 31, 2024 | -$27.51 | N/A |
| Dec 31, 2023 | -$23.45 | -1504.2% |
| Dec 31, 2022 | $1.67 | -94.3% |
| Dec 31, 2021 | $29.35 | +5.8% |
| Dec 31, 2020 | $27.75 | N/A |
| Dec 31, 2019 | -$8.19 | N/A |
| Dec 31, 2018 | -$0.50 | N/A |
| Dec 31, 2017 | -$0.52 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 3,100 words across 5 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 3,102 | 5 | |
| 2026Q1 | Mar 31, 2026 | 3,702 | 5 | |
| 2025Q4 | Dec 31, 2025 | 3,815 | 6 | |
| 2025Q3 | Sep 30, 2025 | 3,779 | 6 | |
| 2025Q2 | Jun 30, 2025 | 3,291 | 5 | |
| 2025Q1 | Mar 31, 2025 | 3,230 | 5 | |
| 2024Q3 | Sep 30, 2024 | 3,006 | 5 | |
| 2024Q2 | Jun 30, 2024 | 2,861 | 5 |
2026Q2 Earnings Call
Opening remarks
Andrew Benson Head of Investor Relations Good afternoon, everyone. Thank you all for participating in today's conference call. On the line today from Co-Diagnostics, we have Dwight H. Egan, Chief Executive Officer, and Brian L. Brown, Chief Financial Officer. Earlier today, Co-Diagnostics released financial results for the second quarter ended 06/30/2026. A copy of the press release is available on the company's website. We will begin with management's prepared remarks and then open up the call to analyst Q&A. Before we begin, we would like to inform listeners that certain statements made by Co-Diagnostics during this call are not historical facts and are forward-looking statements. In addition to diagnostic test developments and clinical evaluation timelines, this includes statements concerning regulatory review and clearance, commercialization plans and timing, international regulatory and manufacturing initiatives, financing and liquidity, and the capabilities and potential uses of the company's technology and data infrastructure. The company's Co-Dx PCR testing platform and related tests are subject to regulatory review, clearance, or authorization and are not currently for sale. Actual outcomes and results may differ materially from what is expressed or implied in any statement. Important factors which could cause actual results to differ materially from those in these forward-looking statements are described in the company's annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, and other filings with the SEC, including under the heading Risk Factors, as well as in today's earnings release. Co-Diagnostics assumes no obligation and expressly disclaims any duty to update any forward-looking statements to reflect events or circumstances occurring after this call or to reflect the occurrence of unanticipated events. In addition, the company may discuss certain non-GAAP financial measures during today's call. These non-GAAP financial measures should not be considered a replacement for and should be read together with GAAP results. We refer you to the company's earnings release issued shortly before this call which contains reconciliations to the non-GAAP financial measures presented to their most comparable GAAP results. At this time, I would like to turn the call over to Co-Diagnostics' Chief Executive Officer, Dwight H. Egan. Dwight.
Dwight H. Egan Chief Executive Officer Thank you everyone for joining us today and for your continued support of Co-Diagnostics. This past quarter marked another important step in our transition from platform development toward commercialization. We continued to advance the regulatory, clinical, commercial, and technology initiatives that support our long-term growth strategy. Over the past several years, we have invested in building a differentiated molecular diagnostics platform. Recently, those investments have translated into solid execution across our highest strategic priorities. The milestones we discussed today reflect continued execution against our long-term strategy.
Frequently Asked Questions About CODX
When is Co-Diagnostics, Inc. Common Stock's next earnings date?
Co-Diagnostics, Inc. Common Stock's next earnings report is expected for Mar 29, 2027.
Did CODX beat earnings estimates last quarter?
Yes. Co-Diagnostics, Inc. Common Stock reported EPS of -$1.02 for the quarter ended Sep 30, 2026, above the -$1.25 estimate, a 18.80% surprise.
What EPS do analysts expect from CODX next quarter?
The consensus EPS estimate for Co-Diagnostics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.28 from 3 analysts.
How often does CODX beat earnings estimates?
Co-Diagnostics, Inc. Common Stock beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +10.38%.
CODX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors